New Molecules of Importance in the Prevention and Treatment of Acne: A Systematic Patent Review (2016-2020)


Cite item

Full Text

Abstract

Background:Acne is a highly prevalent disease that mainly affects the pilosebaceous units associated with sebaceous glands, causing inflammatory skin lesions and affecting the self-esteem, mental health, and quality of life of those who suffer from this disease. Different treatments exist today to prevent, reduce, and improve symptoms; however, over the years, there have been problems with bacterial resistance and slight effectiveness with prolonged use.

Objective:The purpose of this article is based on the review of patents of new products of principal topical administration for the treatment of acne in recent years 2016-2020, to evaluate and analyze novel synthetic molecules and semi-synthetics with potential therapeutic and preventive in the acne treatment.

Methods:A systematic review of patents was conducted through the official database of the European Patent Office - Espacenet, where the search focused on the keywords: \"acne and bacteria\" in the title or abstract. Only patents granted between the years 2016-2020 were included, with products having molecules with a synthetic and semi-synthetic origin, without considering natural, biological products or those used as diagnostic means.

Results:A total of 19 patents were selected, most with principally antimicrobial and antiinflammatory action, where the reduction in the appearance of resistance by C. acnes is verified, and its action is complemented by inhibiting the different pathophysiological mechanisms that lead to the worsening of the disease.

Conclusion:Novel approaches in the treatment and prevention of acne, mainly topically, are focused on the reduction of bacterial resistance and irritation compared to current treatments. The use of combined formulations provides better results with additional benefits, improving treatment times and patient adherence.

About the authors

Daniela Calderón-Pardo

Departamento de Farmacia, Facultad de Ciencias, Universidad Nacional de Colombia

Email: info@benthamscience.net

Mairim Serafini

Department of Pharmacy, Federal University of Sergipe

Email: info@benthamscience.net

Izabel Alves

Department of Pharmacy, Federal University of Bahia

Email: info@benthamscience.net

Diana Aragón

Departamento de Farmacia, Facultad de Ciencias, Universidad Nacional de Colombia

Author for correspondence.
Email: info@benthamscience.net

References

  1. Knutsen-Larson, S.; Dawson, A.L.; Dunnick, C.A.; Dellavalle, R.P. Acne vulgaris: Pathogenesis, treatment, and needs assessment. Dermatol. Clin., 2012, 30(1), 99-106. viii-ix. doi: 10.1016/j.det.2011.09.001 PMID: 22117871
  2. Williams, H.C.; Dellavalle, R.P.; Garner, S. Acne vulgaris. Lancet, 2012, 379(9813), 361-372. doi: 10.1016/S0140-6736(11)60321-8 PMID: 21880356
  3. Beylot, C.; Auffret, N.; Poli, F.; Claudel, J.P.; Leccia, M.T.; Del Giudice, P.; Dreno, B. Propionibacterium acnes: An update on its role in the pathogenesis of acne. J. Eur. Acad. Dermatol. Venereol., 2014, 28(3), 271-278. doi: 10.1111/jdv.12224 PMID: 23905540
  4. Kraft, J.; Freiman, A. Management of acne. CMAJ, 2011, 183(7), E430-5.
  5. Fox, L.; Csongradi, C.; Aucamp, M.; du Plessis, J.; Gerber, M. Treatment modalities for acne. Molecules, 2016, 21(8), 1063. doi: 10.3390/molecules21081063 PMID: 27529209
  6. SC Johnson College of Business, World International Property (WIPO). Global Innovation Index. 13th edition. 2020. Avialable from: https://www.wipo.int/global_innovation_ index/en/2020/
  7. Zhao, J.; Wang, Y.; Jiang, L.; Mu, Y.Z. The application of skin care product in acne treatment. Dermatol. Ther., 2020, 33(6), e14287. doi: 10.1111/dth.14287 PMID: 32897611
  8. International Trade Administration. South Korea – Country Commercial Guide. 2022. Avialable from: https://www. trade.gov/country-commercial-guides/south-korea-cosme-tics
  9. WIPO IP PORTAL. IPC Publication. 2023. Avialable From: https://ipcpub.wipo.int/
  10. Kumazawa, R. Patenting in the Pharmaceutical Industry. Intellectual Property Rights; IntechOpen Limited: London, 2017. doi: 10.5772/68102
  11. Mukherjee, A. Licensing a new product: Fee vs. royalty licensing with unionized labor market. Labour Econ., 2010, 17(4), 735-742. doi: 10.1016/j.labeco.2009.09.003
  12. Ministry of Food and Drug Safety. Cosmetics regulation. 2023. Avialable From: https://www.mfds.go.kr/eng/wpge/m_24/de011014l001.do
  13. Weir, C.B.; Le, J.K. Metronidazole; StatPearls: Treasure Island, 2022.
  14. Lin, A.N.; Reimer, R.J.; Carter, D.M. Sulfur revisited. J. Am. Acad. Dermatol., 1988, 18(3), 553-558. doi: 10.1016/S0190-9622(88)70079-1 PMID: 2450900
  15. Trivedi, M.K.; Bosanac, S.S.; Sivamani, R.K.; Larsen, L.N. Emerging therapies for acne vulgaris. Am. J. Clin. Dermatol., 2018, 19(4), 505-516. doi: 10.1007/s40257-018-0345-x PMID: 29594974
  16. Dréno, B.; Pécastaings, S.; Corvec, S.; Veraldi, S.; Khammari, A.; Roques, C. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: A brief look at the latest updates. J. Eur. Acad. Dermatol. Venereol., 2018, 32(Suppl. 2), 5-14. doi: 10.1111/jdv.15043 PMID: 29894579
  17. Bannatyne, R.M. Metronidazole, its bioactive metabolites and acne. Curr. Med. Res. Opin., 1999, 15(4), 298-299. doi: 10.1185/03007999909116500 PMID: 10640262
  18. Song, M.; Seo, S.H.; Ko, H.C.; Oh, C.K.; Kwon, K.S.; Chang, C.L.; Kim, M.B. Antibiotic susceptibility of Propionibacterium acnes isolated from acne vulgaris in Korea. J. Dermatol., 2011, 38(7), 667-673. doi: 10.1111/j.1346-8138.2010.01109.x PMID: 21352337
  19. Okamoto, K.; Ikeda, F.; Kanayama, S.; Nakajima, A.; Matsumoto, T.; Ishii, R.; Umehara, M.; Gotoh, N.; Hayashi, N.; Iyoda, T.; Matsuzaki, K.; Matsumoto, S.; Kawashima, M. In vitro antimicrobial activity of benzoyl peroxide against Propionibacterium acnes assessed by a novel susceptibility testing method. J. Infect. Chemother., 2016, 22(6), 426-429. doi: 10.1016/j.jiac.2015.12.010 PMID: 26806150
  20. Wang, Y.; Kuo, S.; Shu, M.; Yu, J.; Huang, S.; Dai, A.; Two, A.; Gallo, R.L.; Huang, C.M. Staphylococcus epidermidis in the human skin microbiome mediates fermentation to inhibit the growth of Propionibacterium acnes: Implications of probiotics in acne vulgaris. Appl. Microbiol. Biotechnol., 2014, 98(1), 411-424. doi: 10.1007/s00253-013-5394-8 PMID: 24265031
  21. Kaur-Boparai, J.; Sharma, P.K. Mini review on antimicrobial peptides, sources, mechanism and recent applications. Protein Pept. Lett., 2020, 27(1), 4-16. doi: 10.2174/18755305MTAwENDE80 PMID: 31438824
  22. Malmsten, M. Antimicrobial peptides. Ups. J. Med. Sci., 2014, 119(2), 199-204. doi: 10.3109/03009734.2014.899278 PMID: 24758244
  23. Dréno, B. What is new in the pathophysiology of acne, an overview. J. Eur. Acad. Dermatol. Venereol., 2017, 31(Suppl. 5), 8-12. doi: 10.1111/jdv.14374 PMID: 28805938
  24. Marta Guarna, M.; Coulson, R.; Rubinchik, E. Anti-inflammatory activity of cationic peptides: Application to the treatment of acne vulgaris. FEMS Microbiol. Lett., 2006, 257(1), 1-6. doi: 10.1111/j.1574-6968.2006.00156.x PMID: 16553825
  25. Das, S.; Reynolds, R.V. Recent advances in acne pathogenesis: Implications for therapy. Am. J. Clin. Dermatol., 2014, 15(6), 479-488. doi: 10.1007/s40257-014-0099-z PMID: 25388823
  26. Jugeau, S.; Tenaud, I.; Knol, A.C.; Jarrousse, V.; Quereux, G.; Khammari, A.; Dreno, B. Induction of toll-like receptors by Propionibacterium acnes. Br. J. Dermatol., 2005, 153(6), 1105-1113. doi: 10.1111/j.1365-2133.2005.06933.x PMID: 16307644
  27. Kim, J.; Ochoa, M.T.; Krutzik, S.R.; Takeuchi, O.; Uematsu, S.; Legaspi, A.J.; Brightbill, H.D.; Holland, D.; Cunliffe, W.J.; Akira, S.; Sieling, P.A.; Godowski, P.J.; Modlin, R.L. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J. Immunol., 2002, 169(3), 1535-1541. doi: 10.4049/jimmunol.169.3.1535 PMID: 12133981
  28. Matsuzawa-Ishimoto, Y.; Hwang, S.; Cadwell, K. Autophagy and Inflammation. Annu. Rev. Immunol., 2018, 36(1), 73-101. doi: 10.1146/annurev-immunol-042617-053253 PMID: 29144836
  29. Lee, Y.; Shin, K.; Shin, K.O.; Yoon, S.; Jung, J.; Hwang, E.; Chung, H.J.; Hossini, A.M.; Zouboulis, C.C.; Baek, M.J.; Baek, J.H.; Chi, Y.M.; Lee, S.; Jeong, S. Topical application of autophagy‐activating peptide improved skin barrier function and reduced acne symptoms in acne‐prone skin. J. Cosmet. Dermatol., 2021, 20(3), 1009-1016. doi: 10.1111/jocd.13636 PMID: 32697858
  30. Johnson, B.A.; Nunley, J.R. Topical therapy for acne vulgaris. Postgrad. Med., 2000, 107(3), 69-80, 73-76, 79-80. doi: 10.3810/pgm.2000.03.945 PMID: 10728136
  31. Food and Drug Administration FDA. Cosmetics & U.S. Law. 2022. Avialable from: https://www.fda.gov/cosmetics/cosmetics-laws-regulations/cosmetics-us-law
  32. Jeong, S.; Gue, S.D.; Cha, J.D.; Ko, E.S.; Cho, S.M.; Jung, J.H. Composition for the treatment or improvement of Acne dermatitis comprising 5-aminolevulinic acid hydrochloride and its derivatives. KR Patent KR102171200B1, KR20200058699A, 2020.
  33. Keedon, P.; Chung, H.J.; Heungjae, K.; Kayoung, S.; Juyeon, J.; Beomcheol, K. Beomcheol, A cosmetic and pharmaceutical composition for acne improvement. KR Patent KR20200064762A, 2020.
  34. Chul, H.K.; Yang, K.T.; Mong, L.C.; Kook, L.K. A cosmetic composition for reducing acne and inhibiting sebum secretion containing chrysophanol mangiferin and shikonofuran A. KR Patent KR101987717B1, 2019.
  35. Masatoshi, H.; Keita, M. Acne bacteria biofilm destructive composition. JP Patent JP2020050679A, 2020.
  36. Liu, Y. Acne removing and whitening lotion and preparation method thereof. CN Patent CN105769857A, 2016.
  37. Yinglu, Z. Acne-removing composition and preparation method thereof. CN Patent CN107684530A, 2018.
  38. Xiaohui, C.; Jian, C.; Tianhui, X.; Lijin, Q.; Lijing, B. Antibacterial and anti-inflammation pyridone composition and cosmetic comprising same. CN Patent CN110693754A, CN110693754B, 2020.
  39. Magaña Castro, J.A.; Vázquez Cervantes, L.; Peña, S.P. Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne. US Patent US10792258B2, 2020.
  40. Rudolph, T.; Mueller, T. Use of cyclohexanol derivatives as antimicrobial active ingredients. RU Patent RU2014129611A, 2016.
  41. Masatoshi, H.; Matsushita, R.; Miyama, K. Biofilm formation inhibitor. JP Patent JP2016210751A, 2016.
  42. Young Mog, K.; Hwan, O. J.; Jung Won, K. Composition for preventing or treating Acne containing oligo-chitosan as an effective component. KR Patent KR101838404B1, 2018.
  43. Soung, M. G.; Choi, W. S.; Jun, S.J.; Jeong, Y. P. Cosmetic composition for treating acne. KR Patent KR101689878B1, 2016.
  44. Jeung, P.H. Composition for improving skin acne comprising quercetin and vitamin D. KR Patent KR20180135169A, 2018.
  45. Dabney, P. Methods for treating acne vulgaris. US Patent US10016456B2, US2016015744A1, 2016.
  46. Bommagani, M.; Bhowmick, S. B.; Kane, P.; Dubey, V. Nanoparticulate composition. US Patent US2018036243A1, WO2016135754A1, 2018.
  47. Ping, L.; Morten, O.; Hasling Frandsen, C.; Hanne, M. Non-aqueous topical compositions comprising a halogenated salicylanilide. MX Patent MX2018011249A, 2019.
  48. Cheng, H.; Rui, H.; Kejian, Z. Polypeptide having anti-bacterial and anti-inflammatory activity and application thereof. CN Patent CN106589088A, CN106589088B 2017.
  49. Caires, C. Systems and methods for treating and/or preventing acne. US Patent US11116714B2, 2020.
  50. Jeffry, B. S.; Maxwell, S. Use of anti-bacterial agent for the treatment of epithelial-related conditions. JP Patent JP2017190345A, WO2011060330A1, 2017.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers